Posted by Michael Wonder on 16 Mar 2020
Paratek Pharmaceuticals announces the submission of the pre-emergency use authorisation application to the FDA for Nuzyra (omadacycline)
10 March 2020 - Purchase of the first 2,500 treatment courses of Nuzyra expected in the first half of 2020.
Paratek Pharmaceuticals today announced that a pre-emergency use authorisation application (pre-EUA) for Nuzyra (omadacycline) has been submitted to the U.S. FDA.
With a pre-EUA, FDA could allow for the potential use of Nuzyra during a declared emergency under emergency use authorisation for the treatment and prophylaxis of pulmonary anthrax in a public health emergency.
